EQS-Adhoc: Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals

EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Disposal/Strategic Company
Decision
Marinomed Biotech AG signs agreement for sale of Carragelose business to
French Unither Pharmaceuticals

26-Nov-2024 / 21:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.

══════════════════════════════════════════════════════════════════════════

Korneuburg, Austria, November 26, 2024 – Marinomed Biotech AG (the
“Company”) announces the signing of an agreement for the sale of its
Carragelose business to French Unither Pharmaceuticals (“Unither”), a
leading contract development and manufacturing organization (CDMO) of
medical devices and pharmaceutical products. The contract provides for
upfront and milestone payments of total up to EUR 20 million, depending on
the achievement of defined commercial and operational targets, over the
next two years. As part of the agreement, Marinomed and Unither intend to
enter into a transition service agreement at completion of such
transaction. The proceeds from the sale of the Carragelose business are
planned to finance both the operating business, with increased focus on
the Marinosolv platform, and the restructuring plan agreed upon with the
Company’s creditors on November 14, 2024. The closing of the contract is
inter alia subject to the successful completion of the restructuring
proceedings, the approval by the Company’s Supervisory Board and
shareholders at an extraordinary general meeting. 

+++ End of ad-hoc announcement +++
 

End of Inside Information

══════════════════════════════════════════════════════════════════════════

26-Nov-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

══════════════════════════════════════════════════════════════════════════

Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2038823

 
End of Announcement EQS News Service

2038823  26-Nov-2024 CET/CEST

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender